Recent Updates — MLYS

The Board of Directors appointed Kristine Peterson as a Class I director effective October 19, 2026, with a term expiring at the 2027 annual meeting. She serves on the Audit Committee. Lonnel Coats was appointed as a Class II director effective the same date, with a term expiring at the 2028 annual meeting, and serves on the Compensation Committee. The Board size increased from seven to nine directors. Each new director received standard non-employee compensation grants, including options for 16,600 shares and RSUs for 12,400 shares vesting over three years. Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.

Mineralys Therapeutics reported a net loss of $241.1 million for the quarter ended June 30, 2026, driven by a $200 million upfront payment to Tanabe to eliminate royalty obligations on its hypertension drug lorundrostat. The company raised approximately $150 million through a public offering and drew down an initial $100 million tranche from a $500 million senior secured term loan facility. Cash reserves stood at $661.4 million as of June 30, 2026. Mineralys appointed James J. Ferguson III as Chief Medical Officer effective August 10, 2026, while David Rodman transitioned to a Strategic Advisor role. The company maintains its PDUFA target date for lorundrostat approval at December 22, 2026, and continues commercial launch preparations. Mineralys Therapeutics is a biopharmaceutical company developing treatments for hypertension and aldosterone-related comorbidities.